Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Carcinoembryonic antigen protein + Bacillus Calmette-Guérin
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Intravesical, Intradermal, Subcutaneous, Intramuscular
01
Overview
This entry refers to a combination of two agents used in cancer immunotherapy research and treatment. Carcinoembryonic antigen (CEA) is a glycoprotein involved in cell adhesion that is overexpressed in several cancers, including colorectal cancer. It serves as both a tumor marker and an immunotherapy target. Bacillus Calmette-Guérin (BCG) is a live attenuated strain of Mycobacterium bovis used as an intravesical immunotherapy for non-muscle invasive bladder cancer and as a vaccine against tuberculosis. In oncology research, CEA-targeted vaccines or therapies aim to stimulate the immune system to recognize and attack CEA-expressing tumor cells; BCG acts as an immune stimulant or adjuvant by activating local immune responses that can enhance anti-tumor activity. The combination of CEA-based antigens with BCG has been explored experimentally to boost anti-tumor immunity by combining specific targeting (CEA) with broad immune activation (BCG). This approach remains investigational for most indications outside standard BCG use in bladder cancer.
- Brand names
- TICETheraCys
- Other names
- carcinoembryonic antigenbacillus calmette-guerinBCG vaccine
02
Targets
CEACAM5 (Carcinoembryonic antigen related cell adhesion molecule 5)
Beyond the preview
Go deeper on Carcinoembryonic antigen protein + Bacillus Calmette-Guérin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Carcinoembryonic antigen protein + Bacillus Calmette-Guérin.